Safety of Intravenous Diltiazem in Reduced Ejection Fraction Heart Failure with Rapid Atrial Fibrillation
- 24 February 2018
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 38 (6) , 503-508
Abstract
Diltiazem is a nondihydropyridine calcium channel blocker that is used to control rapid ventricular response in patients who have atrial fibrillation or flutter. Diltiazem has a negative inotropic effect and may cause hemodynamic decompensation in patients with reduced ejection fraction. This study evaluated outcomes in patients who had low ejection fraction and were treated with diltiazem.Keywords
This publication has 22 references indexed in Scilit:
- Safety and efficacy of intravenousdiltiazem in atrial fibrillation or atrial flutterThe American Journal of Cardiology, 1995
- Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failureThe American Journal of Cardiology, 1994
- Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failureThe American Journal of Cardiology, 1991
- Different cardiodepressant potency of various calcium antagonists in human myocardiumThe American Journal of Cardiology, 1990
- Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutterThe American Journal of Cardiology, 1989
- The Effect of Diltiazem on Mortality and Reinfarction after Myocardial InfarctionNew England Journal of Medicine, 1988
- Central and renal hemodynamic effects and hormonal response to diltiazem in severe congestive heart failureThe American Journal of Cardiology, 1987
- Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.Circulation, 1982
- The effects of intravenous verapamil on hemodynamic status of patients with coronary artery disease receiving propranolol.Circulation, 1982
- Nifedipine and left ventricular function in beta-blocked patients.Heart, 1981